Andrea S. Blevins Primeau, PhD, MBA

Researchers sought to determine whether MRD-adapted treatment would be feasible for most patients with MM.

Prior authorization requirements are associated with delays or changes in cancer treatment that negatively impact patients’ well-being and perceptions of the health care system, a new study suggests.

Researchers sought to determine whether magrolimab would be effective in AML combined with azacitidine.

A majority of patients with head and neck cancer develop oral mucositis after intensity-modulated radiation therapy, a study suggests.

New data suggest that, among Americans aged 35 to 54 years, lung cancer is now more common in women than in men.

Opioid use is declining in American cancer patients but at a lower rate than in patients without cancer, data suggest.

Individual participant data packages for cancer trials are often incomplete, a new study suggests.

Results from the PATHFINDER study suggest that MCED testing is feasible in practice, but more research is needed to assess its clinical utility.

Objective and subjective hearing loss is more common in cancer survivors than in the general population, a study suggests.

Tislelizumab may be a first-line treatment option for patients with unresectable hepatocellular carcinoma, according to researchers.